Naturally occurring anthraquinones: Chemistry and therapeutic potential in autoimmune diabetes

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Chien, Shih Chang ^a   Wu, Yueh Chen ^b   Chen, Zeng Weng ^c   Yang, Wen Chin ^a,b,c,d,e,f  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^c Animal Technology Institute   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE;

AUTOIMMUNE DISEASE; BIOSYNTHESIS; CHEMOTAXIS; DIABETES MELLITUS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOREGULATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84926355561     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/357357     Document Type: Review

References (70)

1. International Diabetes Foundation Committee, "IDF DIABETES ATLAS" 2013.
2. T. Cha, L. Qiu, C. Chen, Y. Wen, and M. Hung, "Emodin downregulates androgen receptor and inhibits prostate cancer cell growth" Cancer Research, vol. 65, no. 6, pp. 2287-2295, 2005.
3. L. A. O'Reilly, P. R. Hutchings, P. R. Crocker et al., "Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression" European Journal of Immunology, vol. 21, no. 5, pp. 1171-1180, 1991.
4. M. Lodoen, K. Ogasawara, J. A. Hamerman et al., "NKG2Dmediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules" Journal of Experimental Medicine, vol. 197, no. 10, pp. 1245-1253, 2003.
5. D. L. Eizirik, M. L. Colli, and F. Ortis, "The role of inflammation in insulitis and-cell loss in type 1 diabetes" Nature Reviews Endocrinology, vol. 5, no. 4, pp. 219-226, 2009.
6. D. Bresson and M. von Herrath, "Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?" Autoimmunity Reviews, vol. 6, no. 5, pp. 315-322, 2007.
7. M. A. Atkinson and S. Brian Wilson, "Fatal attraction: chemokines and type 1 diabetes"The Journal of Clinical Investigation, vol. 110, no. 11, pp. 1611-1613, 2002.
8. L. M. Bradley, V. C. Asensio, L. Schioetz et al., "Islet-specific Th1, but notTh2, cells secretemultiple chemokines and promote rapid induction of autoimmune diabetes" Journal of Immunology, vol. 162, no. 5, pp. 2511-2520, 1999.
9. M. J. Cameron, G. A. Arreaza, M. Grattan et al., "Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes" Journal of Immunology, vol. 165, no. 2, pp. 1102-1110, 2000.
10. C. Meagher, S. Sharif, S. Hussain, M. J. Cameron, G. A. Arreaza, and T. L. Delovitch, "Cytokines and chemokines in the pathogenesis of murine Type 1 diabetes" Advances in Experimental Medicine and Biology, vol. 520, pp. 133-158, 2003.
11. A. Vetere, A. Choudhary, S. M. Burns, and B. K. Wagner, "Targeting the pancreatic β-cell to treat diabetes" Nature Reviews Drug Discovery, vol. 13, pp. 278-289, 2014.
12. C. L. Chang, Y. C. Chen, H. M. Chen, N. S. Yang, and W. C. Yang, "Natural cures for type 1 diabetes: a review of phytochemicals, biological actions, and clinical potential" Current Medicinal Chemistry, vol. 20, no. 7, pp. 899-907, 2013.
13. S. J. Allen, S. E. Crown, and T. M. Handel, "Chemokine: receptor structure, interactions, and antagonism" Annual Review of Immunology, vol. 25, pp. 787-820, 2007.
14. A. E. I. Proudfoot, "Chemokine receptors: multifaceted therapeutic targets" Nature Reviews Immunology, vol. 2, no. 2, pp. 106-115, 2002.
15. T. Jin, X. Xu, and D. Hereld, "Chemotaxis, chemokine receptors and human disease" Cytokine, vol. 44, no. 1, pp. 1-8, 2008.
16. C. Murdoch and A. Finn, "Chemokine receptors and their role in inflammation and infectious diseases" Blood, vol. 95, no. 10, pp. 3032-3043, 2000.
17. J. E. Pease and T. J. Williams, "The attraction of chemokines as a target for specific anti-inflammatory therapy" British Journal of Pharmacology, vol. 147, no. 1, pp. S212-S221, 2006.
18. J. E. Turner, O. M. Steinmetz, R. A. Stahl, and U. Panzer, "Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases" Mini-Reviews in Medicinal Chemistry, vol. 7, no. 11, pp. 1089-1096, 2007.
19. U. Christen, "Chemokines as drug targets in type 1 diabetes" Endocrine, Metabolic and ImmuneDisorders-Drug Targets, vol. 7, no. 1, pp. 7-12, 2007.
20. E. de Clercq, "The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)" Biochemical Pharmacology, vol. 77, no. 11, pp. 1655-1664, 2009.
21. H. Toyoda and B. Formby, "Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model" BioEssays, vol. 20, no. 9, pp. 750-757, 1998.
22. S. K. Bromley, T. R. Mempel, and A. D. Luster, "Orchestrating the orchestrators: chemokines in control of T cell traffic" Nature Immunology, vol. 9, no. 9, pp. 970-980, 2008.
23. E. Aboumrad, A. M. Madec, and C. Thivolet, "The CXCR4/CXCL12 (SDF-1) signalling pathway protects nonobese diabetic mouse from autoimmune diabetes" Clinical an Experimental Immunology, vol. 148, no. 3, pp. 432-439, 2007.
24. C. Carvalho-Pinto, M. I. García, L. Gomez et al., "Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice" European Journal of Immunology, vol. 34, no. 2, pp. 548-557, 2004.
25. C. Hagemann, R. Patel, and J. L. Blank, "MEKK3 interacts with the PA28 regulatory subunit of the proteasome" Biochemical Journal, vol. 373, no. 1, pp. 71-79, 2003.
26. Y. Yamada, Y. Okubo, A. Shimada et al., "Acceleration of diabetes development in CXC chemokine receptor 3 (CXCR3)-deficientNODmice" Diabetologia, vol. 55, no. 8, pp. 2238-2245, 2012.
27. M. Solomon, B. Balasa, and N. Sarvetnick, "CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse" Autoimmunity, vol. 43, no. 2, pp. 156-163, 2010.
28. M. Y. Shen, Y. P. Lin, B. C. Yang et al., "Catenarin prevents type 1 diabetes in nonobese diabetic mice via inhibition of leukocyte migration involving the MEK6/p38 andMEK7/JNK pathways" Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID982396, 13 pages, 2012.
29. J. Morimoto, H. Yoneyama, A. Shimada et al., "CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced β cell proliferation without affecting insulitis"The Journal of Immunology, vol. 173, no. 11, pp. 7017-7024, 2004.
30. G. J. Lin, S. H. Huang, Y. W. Chen et al., "Transgenic expression of murine chemokine decoy receptor D6 by islets reveals the role of inflammatory CC chemokines in the development of autoimmune diabetes in NOD mice" Diabetologia, vol. 54, no. 7, pp. 1777-1787, 2011.
31. M. A. Kriegel, C. Rathinam, and R. A. Flavell, "Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells" Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3457-3462, 2012.
32. R. Singh and S. M. Chauhan, "9, 10-Anthraquinones and other biologically active compounds from the genus Rubia" Chemistry and Biodiversity, vol. 1, no. 9, pp. 1241-1264, 2004.
33. R. A. Muzychkina, NaturalAnthraquinones, PHASISPublishing House, Moscow, Russia, 1998.
34. A. Mathey, P. Spiteller, and W. Steglich, "Draculone, a new anthraquinone pigment from the tropical lichen Melanotheca cruenta" Zeitschrift furNaturforschung C: Journal of Biosciences, vol. 57, no. 7-8, pp. 565-567, 2002.
35. V. Ivanova, R. Schlegel, and U. Grafe, "2-Methoxy-4, 5, 7-trihydroxy-anthraquinone, a new lichen metabolite produced by Xanthoria parietina" Die Pharmazie, vol. 55, no. 10, pp. 785-786, 2000.
36. S. Kanokmedhakul, K. Kanokmedhakul, N. Phonkerd, K. Soytong, P. Kongsaeree, and A. Suksamrarn, "Antimycobacterial anthraquinone-chromanone compound and diketopiperazine alkaloid from the fungus Chaetomium globosum KMITLN0802" Planta Medica, vol. 68, no. 9, pp. 834-836, 2002.
37. Y. Yang, Y. M. Yan, W. Wei et al., "Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy" Bioorganic andMedicinal Chemistry Letters, vol. 23, no. 13, pp. 3905-3909, 2013.
38. J. Westendorf, B. Poginsky, H. Marquardt, and L. Kraus, "Possible carcinogenicity of anthraquinone-containingmedical plants" Planta Medica, vol. 54, p. 562, 1988.
39. Y. Han, R. van der Heijden, A. W. M. Lefeber, C. Erkelens, and R. Verpoorte, "Biosynthesis of anthraquinones in cell cultures of Cinchona "Robusta" proceeds via the methylerythritol 4-phosphate pathway" Phytochemistry, vol. 59, no. 1, pp. 45-55, 2002.
40. P. Tuntiwachwuttikul, Y. Butsuri, P. Sukkoet, U. Prawat, and W. C. Taylor, "Anthraquinones from the roots of Prismatomeris malayana" Natural Product Research, vol. 22, no. 11, pp. 962-968, 2008.
41. A. Koyama, K. Sasou, H. Nakao et al., "Pulmonary intralobar sequestration accompanied by aneurysm of an anomalous arterial supply" Internal Medicine, vol. 31, no. 7, pp. 946-950, 1992.
42. Y. Kawasaki, Y. Goda, and K. Yoshihira, "The mutagenic constituents of Rubia tinctorum" Chemical and Pharmaceutical Bulletin, vol. 40, no. 6, pp. 1504-1509, 1992.
43. M. J. Liou and T. S. Wu, "Triterpenoids from Rubia yunnanensis" Journal of Natural Products, vol. 65, no. 9, pp. 1283-1287, 2002.
44. G. C. H. Derksen, H. A. G. Niederländer, and T. A. Van Beek, "Analysis of anthraquinones in Rubia tinctorum L. by liquid chromatography coupled with diode-array UV and mass spectrometric detection" Journal of Chromatography A, vol. 978, no. 1-2, pp. 119-127, 2002.
45. V. V. Murti and T. R. Seshadri, "Naturally occurring less common amino acids of possible nutritional interest and their simpler derivatives" Nutrition abstracts and reviews, vol. 37, no. 3, pp. 677-693, 1967.
46. S. X. Wang, H. M. Hua, L. J. Wu, X. Li, and T. R. Zhu, "Studies on anthraquinones from the roots of rubia cordifolia" Acta Pharmaceutica Sinica, vol. 27, no. 10, pp. 743-747, 1992.
47. A. A. El-Gamal, K. Takeya, H. Itokawa et al., "Anthraquinones from the polar fractions of Galium sinaicum" Phytochemistry, vol. 42, no. 4, pp. 1149-1155, 1996.
48. A. M. Vidal-Tessier, P. Delaveau, and B. Champion, "New quinones from the roots of Rubia cordifolia L" Annales Pharmaceutiques Francaises, vol. 44, no. 2, pp. 117-122, 1986.
49. A. M. Vidal-Tessier, P. Delaveau, and B. Champion, "New anthraquinones of Rubia cordifolia L." Annales Pharmaceutiques Francaises, vol. 45, no. 3, pp. 261-267, 1987.
50. C. Dosseh, A. M. Tessier, and P. Delaveau, "Rubia cordifolia roots. II: new quinones" Planta Medica, vol. 43, no. 2, pp. 141-147, 1981.
51. C. Dosseh, A. M. Tessier, and P. Delaveau, "New quinones in Rubia cordifolia L. Roots, III" Planta Medica, vol. 43, pp. 360-366, 1981.
52. K. Xiao, L. Xuan, Y. Xu, D. Bai, and D. Zhong, "Constituents from Polygonum cuspidatum" Chemical and Pharmaceutical Bulletin, vol. 50, no. 5, pp. 605-608, 2002.
53. R. Chen, J. Zhang, Y. Hu, S. Wang, M. Chen, and Y. Wang, "Potential antineoplastic effects of Aloe-emodin: a comprehensive review" The American Journal of Chinese Medicine, vol. 42, pp. 275-288, 2014.
54. H. Dave and L. Ledwani, "A review on anthraquinones isolated from Cassia species and their applications" Indian Journal of Natural Products and Resources, vol. 3, no. 3, pp. 291-319, 2012.
55. S. Lin, W. Lai, C. Ho et al., "Eniodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways" Anticancer Research, vol. 29, no. 1, pp. 327-335, 2009.
56. L. C. Chang, H. M. Sheu, Y. S. Huang, T. R. Tsai, and K. W. Kuo, "A novel function of emodin: enhancement of the nucleotide excision repair of UV-and cisplatin-induced DNA damage in human cells" Biochemical Pharmacology, vol. 58, no. 1, pp. 49-57, 1999.
57. Y. Ding, L. Zhao, H. Mei et al., "Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway" European Journal of Pharmacology, vol. 590, no. 1-3, pp. 377-386, 2008.
58. Y. L. Leu, T. L. Hwang, J. W. Hu, and J. Y. Fang, "Anthraquinones from Polygonum cuspidatum as tyrosinase inhibitors for dermal use" Phytotherapy Research, vol. 22, no. 4, pp. 552-556, 2008.
59. X. Chu, A. Sun, and R. Liu, "Preparative isolation and purification of five compounds from the Chinese medicinal herb Polygonum cuspidatum Sieb. et Zucc by high-speed countercurrent chromatography" Journal of Chromatography A, vol. 1097, no. 1-2, pp. 33-39, 2005.
60. H. Matsuda, H. Shimoda, T. Morikawa, and M. Yoshikawa, "Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity" Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 14, pp. 1839-1842, 2001.
61. G. S. Jayatilake, H. Jayasuriya, E.-. Lee et al., "Kinase inhibitors from Polygonum cuspidatum" Journal of Natural Products, vol. 56, no. 10, pp. 1805-1810, 1993.
62. H. Jayasuriya, N. M. Koonchanok, R. L. Geahlen, J. L. McLaughlin, and C. J. Chang, "Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum" Journal of Natural Products, vol. 55, no. 5, pp. 696-698, 1992.
63. L. Zhang, Y. K. Lau, L. Xi et al., "Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties" Oncogene, vol. 16, no. 22, pp. 2855-2863, 1998.
64. M. Bachmann, P. Blaser, J. Luthy, and C. Schlatter, "Toxicity and mutagenicity of anthraquinones from Aspergillus chevalieri" Journal of Environmental Pathology, Toxicology and Oncology, vol. 11, no. 2, pp. 49-52, 1992.
65. C. Zhang, X. Wang, X. Zhang, Y. Zhang, H. Xiao, and X. Liang, "Bioassay-guided separation of citreorosein and other oestrogenic compounds from Polygonum cuspidatum" Phytotherapy Research, vol. 23, no. 5, pp. 740-741, 2009.
66. R. Bösch, U. Friederich, W. K. Lutz, E. Brocker, M. Bachmann, and C. Schlatter, "Investigations onDNAbinding in rat liver and in Salmonella and onmutagenicity in the Ames test by emodin, a natural anthraquinone" Mutation Research, vol. 188, no. 3, pp. 161-168, 1987.
67. M. Y. Shen, Y. J. Liu, M. J. Don et al., "Combinedphytochemistry and chemotaxis assays for identification and mechanistic analysis of anti-inflammatory phytochemicals in Fallopia japonica" PLoS ONE, vol. 6, no. 11, Article ID e27480, 2011.
68. M. Nguyen, M. Dougados, L. Berdah, and B. Amor, "Diacerhein in the treatment of osteoarthritis of the hip" Arthritis and Rheumatism, vol. 37, no. 4, pp. 529-536, 1994.
69. G. Srinivas, S. Babykutty, P. P. Sathiadevan, and P. Srinivas, "Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent" Medicinal Research Reviews, vol. 27, no. 5, pp. 591-608, 2007.
70. "Danthron" in Report on Carcinogens, pp. 128-129, Department of Health and Human Services, National Toxicology Program, 12th edition, 2011.